Categories Determined by Chart Review for Samples and Patients Included in the Analysis
Category . | Samples . | Unique Patients . |
---|---|---|
Never SARS-CoV-2 positive | 1416 | 1249 |
Same-day negative test | 194 | 194 |
Ever SARS-CoV-2 positivea | 444 | 360 |
Convalescent | 182 | 153 |
Late presenting | 30 | 30 |
Acute | 141 | 130 |
Sampled 3 or more days prior to diagnosis | 42 | 34 |
Negative interim testing | 21 | 16 |
Category . | Samples . | Unique Patients . |
---|---|---|
Never SARS-CoV-2 positive | 1416 | 1249 |
Same-day negative test | 194 | 194 |
Ever SARS-CoV-2 positivea | 444 | 360 |
Convalescent | 182 | 153 |
Late presenting | 30 | 30 |
Acute | 141 | 130 |
Sampled 3 or more days prior to diagnosis | 42 | 34 |
Negative interim testing | 21 | 16 |
Includes in-hospital nucleic acid amplification tests (NAAT) as well as community NAAT or antigen testing if reported in the clinical narrative.
Categories Determined by Chart Review for Samples and Patients Included in the Analysis
Category . | Samples . | Unique Patients . |
---|---|---|
Never SARS-CoV-2 positive | 1416 | 1249 |
Same-day negative test | 194 | 194 |
Ever SARS-CoV-2 positivea | 444 | 360 |
Convalescent | 182 | 153 |
Late presenting | 30 | 30 |
Acute | 141 | 130 |
Sampled 3 or more days prior to diagnosis | 42 | 34 |
Negative interim testing | 21 | 16 |
Category . | Samples . | Unique Patients . |
---|---|---|
Never SARS-CoV-2 positive | 1416 | 1249 |
Same-day negative test | 194 | 194 |
Ever SARS-CoV-2 positivea | 444 | 360 |
Convalescent | 182 | 153 |
Late presenting | 30 | 30 |
Acute | 141 | 130 |
Sampled 3 or more days prior to diagnosis | 42 | 34 |
Negative interim testing | 21 | 16 |
Includes in-hospital nucleic acid amplification tests (NAAT) as well as community NAAT or antigen testing if reported in the clinical narrative.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.